retatrutide clinical trial dosing ESC 2024: improves lipid and cardiovascular risk profile in Phase II Retatrutide just posted the biggest

& Pfeiffer, A

Supplements help fill the gapsespecially for energy, protein, and digestionso you get results without burnout

This unique trifecta of receptor affinity makes Retatrutide a significant focus in biochemical research involving multi-pathway endocrine signaling

Because retatrutide does not currently hold regulatory approval in the UK, there are no formal prescribing eligibility criteria in the way that exist for licensed medicines

Note that this study showed promotion of wound healing (positive effect), while later papers (Semersky 2025) hypothesize that chronic activation may produce different effects similar to glucocorticoid-induced atrophy

Maintenance is not a passive phase